Expect a sharp sell-off on the Phase 3 miss as the market reprices the stock without apazunersen upside. Monitor the expense reduction plan details and any potential pipeline salvage moves; the commercial business support language suggests management is pivoting to existing revenue streams.
Price Chart
Executive Summary
Ultragenyx announced that its Phase 3 Aspire study for apazunersen (GTX-102) in Angelman syndrome failed to meet the primary endpoint (Bayley-4 cognitive raw score) and the key secondary endpoint (MDRI). The company will evaluate the program's disposition and implement significant expense reductions while supporting its commercial business. This is a major pipeline setback for a company with a $2.5B market cap that was likely pricing in some probability of success for this high-profile asset.
Key Facts
- Phase 3 Aspire study for apazunersen (GTX-102) in Angelman syndrome did not achieve the primary endpoint of change from Baseline in Bayley-4 cognitive raw score.
- The study also failed the key secondary endpoint of net response in Multidomain Responder Index (MDRI).
- No differences were observed between treated and control groups supporting efficacy in Bayley Cognition raw scores or MDRI.
- Safety profile was consistent with Phase 1/2.
- Company will evaluate the apazunersen program for disposition and implement significant expense reductions while supporting its growing commercial business.
Financial Impact
Phase 3 failure likely eliminates a major pipeline value driver; company will take significant expense reductions but no specific dollar amounts provided.
Risk Factors
- Complete write-off of apazunersen program value
- Potential for further pipeline setbacks if expense reductions impact other programs
- Uncertainty around magnitude and timing of expense reductions
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-380165 |
| Document: 0001193125-26-380165-index.html | 0001193125-26-380165 |
| Document: 0001193125-26-380165.txt | 0001193125-26-380165 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 4w ago | 8-K | $14.85 $15.22 | ▼ −2.49% | ▼ −3.68% | $15.22 (−2.49%) |
Sep 1, 2026 4w ago | Press Release | $26.53 $15.03 | ▼ −43.35% | ▼ −43.02% | $15.22 (−42.63%) |
Aug 11, 2026 7w ago | 8-K | $26.80 $14.31 | ▼ −46.60% | ▼ −45.55% | $15.22 (−43.21%) |
Aug 4, 2026 8w ago | 8-K | $24.93 $26.53 | ▲ +6.42% | ▲ +7.02% | $15.22 (−38.95%) |
Aug 4, 2026 8w ago | Insider Cluster | $25.81 $25.81 | · 0.00% | ▲ +1.24% | $15.22 (−41.03%) |
Jun 15, 2026 15w ago | Insider Cluster | $24.85 $32.03 | ▲ +28.89% | ▲ +28.69% | $15.22 (−38.75%) |
Jun 11, 2026 16w ago | Institutional Cluster | $23.98 $34.61 | ▲ +44.33% | ▲ +42.44% | $15.22 (−36.53%) |
May 5, 2026 21w ago | Press Release | $25.93 $22.41 | ▲ +13.57% | ▲ +16.36% | $15.22 (+41.30%) |
May 1, 2026 22w ago | Insider Cluster | $24.77 $22.85 | ▼ −7.75% | ▼ −13.04% | $15.22 (−38.55%) |
Apr 2, 2026 26w ago | 8-K | $22.45 $24.69 | ▲ +9.98% | ▲ +0.10% | $15.22 (−32.20%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access